Abstract.
In the last decade intensive research has been conducted to determine the role of innate immunity host defense peptides (also termed antimicrobial peptides) in the killing of prokaryotic and eukaryotic cells. Many antimicrobial peptides damage the cellular membrane as part of their killing mechanism. However, it is not clear what makes cancer cells more susceptible to some of these peptides, and what the molecular mechanisms underlying these activities are. Two general mechanisms were suggested: (i) plasma membrane disruption via micellization or pore formation, and (ii) induction of apoptosis via mitochondrial membrane disruption. To be clinically used, these peptides need to combine high and specific anticancer activity with stability in serum. Although so far very limited, new studies have paved the way for promising anticancer host defense peptides with a new mode of action and with a broad spectrum of anticancer activity.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 21 December 2004; received after revision 28 January 2005; accepted 1 February 2005
Rights and permissions
About this article
Cite this article
Papo, N., Shai, Y. Host defense peptides as new weapons in cancer treatment. CMLS, Cell. Mol. Life Sci. 62, 784–790 (2005). https://doi.org/10.1007/s00018-005-4560-2
Issue Date:
DOI: https://doi.org/10.1007/s00018-005-4560-2